PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Profitability reveals how effectively the business turns revenues into profits. Higher and improving margins or returns on capital suggest a durable competitive advantage, supporting a stronger intrinsic valuation.
9.86%
ROE below 50% of AVXL's 51.59%. Michael Burry would look for signs of deteriorating business fundamentals.
-447.55%
Both firms have negative ROA. Martin Whitman would investigate if the market environment is extremely challenging.
28.09%
ROCE 50-75% of AVXL's 48.81%. Martin Whitman would worry if management fails to deploy capital effectively.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.